NOX ASX · Health Care

Noxopharm Ltd

Announcements, last 12 months: 51
Price sensitive, last 12 months: 24

Latest announcements

Released	Headline	Actions
16 Oct 2026, 11:50 AM	2026 AGM Letter of Access, Notice of Meeting and Proxy
16 Oct 2026, 10:45 AM	Appendix 4G and Corporate Governance Statement
16 Oct 2026, 10:32 AM	Annual Report to shareholders
8 Oct 2026, 8:15 AM	FDA feedback supports SOF-SKN Phase II plans
30 Sep 2026, 4:05 PM	Audited Financial Statements
14 Sep 2026, 8:23 AM	SOF-SKN to progress to extension study in CLE patients
4 Sep 2026, 8:11 AM	Investor Presentation September 2026
1 Sep 2026, 9:36 AM	Novel oligonucleotides data presented at Options Conference Price sensitive	AI summary
28 Aug 2026, 4:34 PM	Appendix 4E - Preliminary Financial Report Price sensitive	AI summary
26 Aug 2026, 8:06 AM	New preclinical data supports immuno-oncology approach Price sensitive	AI summary

Sign in to see all NOX announcements.

Guidance history

22 Jul 2026	Noxopharm Ltd expects to require additional funding to sustain R&D activities.
27 Apr 2026	Noxopharm did not provide any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in the announcement.
24 Apr 2026	The company continues to be vigilant with its cash resources and is exploring a range of options in relation to securing additional capital to sustain the anticipated level of R&D activities.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow NOX to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.